Cemsidomide

Cemsidomide (CFT7455) is a ubiquitin ligase pathway based IKZF1/3 (Ikaros/Aiolos) degrader with molecular glue activity[1]. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM) [1][2].

Product Specifications

CAS Number

[2504235-67-8]

Product Name Alternative

CFT7455

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IKZF Family; Molecular Glues

Type

Reference compound

Related Pathways

Immunology/Inflammation; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cemsidomide.html

Concentration

10mM

Purity

99.54

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N([C@]2([H])C(NC(CC2)=O)=O)C3=CC=C(C4=CC=CC1=C43)CC5=CC=C(C=C5)CN6CCOCC6

Molecular Formula

C28H27N3O4

Molecular Weight

469.53

Precautions

H302, H315, H319, H335

References & Citations

[1]David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.|[2]James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement) : LB007.